GENE ONLINE|News &
Opinion
Blog

2025-04-24|

Roche and Merck Navigate Tariff Headwinds as NEJM Faces U.S. Attorney Inquiry

by Mark Chiang
Share To

NEWSFLASH

Roche and Merck face tariff challenges, while the New England Journal of Medicine (NEJM) is under scrutiny from a U.S. Attorney. These are the key developments emerging in the pharmaceutical industry today. Specifically, both Roche and Merck are reportedly grappling with issues related to tariffs, impacting their business operations. Separately, the NEJM is fielding inquiries from a U.S. Attorney, the reason for which was not stated.

Newsflash | Powered by GeneOnline AI
Date: April 24, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
A Look at Taiwan-German Collaborative Solutions in Precision Medicine, Drug Development, and Medical Tech
2025-05-21
LATEST
A Look at Taiwan-German Collaborative Solutions in Precision Medicine, Drug Development, and Medical Tech
2025-05-21
ACOG Updates Pain Management Guidelines for IUD Insertions as Novavax Vaccine Gains Approval
2025-05-20
NIH Restores Research Funding to Previously Defunded Scientists Amid Policy Shifts
2025-05-20
Prime Medicine Reduces Workforce by 25 Percent and Appoints David Schenkein as New CEO
2025-05-20
UnitedHealth Group Stock Drops Amid Rising Medicare Advantage Costs and Regulatory Debates
2025-05-20
Trump Science Adviser Michael Kratsios Calls for Renewed Focus on Reproducible Research Practices to Address Scientific Stagnation
2025-05-20
House Republicans Propose $700 Billion Medicaid Savings with Work Requirements
2025-05-20
EVENT
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
2025-06-16
US BIO International Convention
Boston, U.S.A.
Scroll to Top